Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 UCB's Cimzia Gains Approval for RA | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

UCB’s Cimzia Gains Approval for RA

Enzon Pharmaceuticals, Inc. received approval from the FDA for Cimzia for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Enzon Pharmaceuticals, Inc. received approval from the FDA for Cimzia for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). Cimzia (certolizumab pegol), is a PEGylated anti-TNFa (Tumor Necrosis Factor alpha). The product is currently being developed by UCB. Cimzia is one of several products that use Enzon’s PEGylation technology.

“Our PEGylation technology continues to enable very important therapeutics like Cimzia, benefiting patients with a wide variety of diseases,” said Jeffrey H. Buchalter, Enzon’s chairman and chief executive officer.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters